ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is a commercial-stage multispecialty pharmaceutical company. It discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. The company offers products to treat allergies and serious diseases of the eye; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company’s marketed products comprise of BROMDAY, a bromfenac ophthalmic solution for the treatment of postoperative inflam... mation and reduction of ocular pain in patients who have undergone cataract extractions; BEPREVE, a bepotastine besilate ophthalmic solution for ocular itching associated with allergic conjunctivitis; ISTALOL, a timolol maleate ophthalmic solution for the treatment of glaucoma; and VITRASE, a hyaluronidase injection for use as a spreading agent. Its products under development include OTC artificial tear products to treat dry eye and other ocular conditions; PROLENSA, a bromfenac ophthalmic solution for the treatment of postoperative inflammation and reduction of ocular pain after cataract extractions; T-PRED for steroid responsive inflammation; BEPOMAX and BEPOSONE nasal sprays for treating allergic rhinitis; and Bromfenac Adjunct for age-related macular degeneration. In addition, the company develops iganidipine to enhance ocular nerve blood flow; latanoprost, a prostaglandin for the treatment of glaucoma; and ecabet sodium for the treatment of dry eye. ISTA Pharmaceuticals sells its products to drug wholesalers; retailers and distributors such as chain drug stores, hospitals, clinics, and government agencies; and managed healthcare providers including health maintenance organizations and other institutions. ISTA Pharmaceuticals was founded in 1992 and is headquartered in Irvine, California. As of June 5, 2012, ISTA Pharmaceuticals operates as a subsidiary of Bausch & Lomb Incorporated.